- Home
- SRV vs DTIL Comparison
SRV vs DTIL Comparison
Compare SRV & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRV | DTIL |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.9M | 214.7M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SRV | DTIL |
|---|---|---|
| Price | $48.79 | $7.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 62.1K | ★ 623.8K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.11 | $3.53 |
| 52 Week High | $51.54 | $9.62 |
Technical Indicators
Market Signals| Indicator | SRV | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 48.32 | 47.27 |
| Support Level | $48.09 | $6.30 |
| Resistance Level | $50.93 | $8.08 |
| Average True Range (ATR) | 1.35 | 0.64 |
| MACD | -0.19 | -0.14 |
| Stochastic Oscillator | 26.24 | 14.66 |
Price Performance
Historical ComparisonAbout SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end investment company. Its investment objective is to obtain a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in a portfolio of midstream energy investments.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).